White House health advisor Dr. Anthony Fauci said Wednesday that data from a coronavirus drug trial testing Gilead Sciences‘ antiviral drug remdesivir showed “quite good news.”
Speaking to reporters from the White House, Fauci said he was told data from the trial showed a “clear cut positive effect in diminishing time to recover.”
“This will be the standard of care,” Fauci, director of the National Institute of Allergy and Infectious Disease, added.
U.S. health officials are expected to release the full results of a drug trial conducted by the National Institute of Allergy and Infectious Diseases later Wednesday. Gilead Sciences announced earlier in the day that the study had met its primary endpoint, but did not provide further details.
Gilead also released preliminary results from its own study, showing at least 50% of the patients treated with a five-day dosage of remdesivir improved. The clinical trial involved 397 patients with severe cases of Covid-19. The severe study is…